


Amendments to the Claims:

Please cancel claims 3 to 5 and 10 and add new claims 12 to 16 as forth hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A method for the preparation of *trans*- or *cis*-diammoniumdichlorodihydroxoplatinum(IV) or derivatives thereof,  
~~characterized in that wherein~~  
*trans*- or *cis*-diammoniumdichloroplatinum(II) is reacted with a solution comprising >30% peroxide at temperatures below 30°C, and  
the product thus obtained is dissolved in a mineral acid and subsequently precipitated with an alkaline solution.
2. (Currently Amended) A compound of general formula



wherein  $X_1, X_2$  = calcium, magnesium, sodium, potassium, lithium ions, alkyl and/or aryl residues.

3. to 5. (canceled)
6. (Original) A pharmaceutical agent, comprising a compound according to claim 2, optionally together with a pharmaceutically tolerable carrier, adjuvant and/or vehicle.

7. (Currently Amended) The pharmaceutical agent according to ~~the preceding claim,~~  
~~characterized in that~~

claim 6, wherein the carriers are ~~selected from the group comprising~~  
fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption  
enhancers, wetting agents, adsorbents and/or lubricants.

8. (Currently Amended) The pharmaceutical agent according to ~~any of the preceding~~  
~~claims,~~  
~~characterized in that~~

claim 6, wherein

the carriers are liposomes, siosomes and/or niosomes.

9. (Original) A kit comprising the compounds according to claim 2, optionally together  
with information for combining the contents of the kit.

10. (canceled)

11.(New) A method for prophylaxis, therapy, follow-up and aftercare of a disease  
associated with cell growth, cell differentiation and/or cell division comprising

administering the compound of claim 2 to a person in need of such  
prophylaxis, therapy, follow-up or aftercare for a disease associated with cell growth,  
cell differentiation and/or cell division in a prophylactically, therapeutically, follow-up or  
aftercare effective amount.

12.(New) The method of claim 11, wherein said disease is a tumor.

13.(New) The method of claim 11, wherein the compound is administered orally,  
vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly,  
intraperitoneally, regionally and/or topically.

14.(New) The method of claim 12, wherein the compound is administered orally,  
vaginally, rectally, nasally, subcutaneously, intravenously, intramuscularly,

intraperitoneally, regionally and/or topically.

15. (New) A combination tumor therapy comprising  
administering the compound of claim 2 to a person in need of such therapy in  
a therapeutically effective amount, and  
subjecting said person to a second tumor treatment.

16. (New) The combination therapy of claim 15, wherein said second tumor treatment is  
chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.